文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

ICU患者丙戊酸蛋白结合率高度可变且全血浓度无法预测

Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review.
PubMed 文献 · Pharmacotherapy · 2017-03-16

本研究为观察性病例系列,纳入15例血清白蛋白低于4 g/dl的ICU患者,同步测定丙戊酸总浓度和游离浓度。结果显示无患者游离分数在5-10%的正常范围,中位游离分数为48%(范围15-89%),总浓度与游离浓度相关性差(r=0.43),仅2例分类一致。白蛋白校正方程预测游离浓度效果不佳(r=0.45)。

要点

  • ICU患者丙戊酸游离分数中位48%,远高于正常5-10%。
  • 总浓度与游离浓度相关性差(r=0.43),不能替代游离浓度监测。
  • 白蛋白校正方程预测游离浓度不佳(r=0.45),临床需直接测游离浓度。

核心结论

  • ICU患者丙戊酸蛋白结合率高度不一致,总浓度不能预测游离浓度,即使经白蛋白校正。

研究设计与样本

  • 观察性研究,连续纳入ICU患者,纳入标准为使用丙戊酸且血清白蛋白低于4 g/dl,共15例(男性9例)。

主要发现

  • 中位年龄63岁(范围34-70岁),丙戊酸剂量为3 g/天(35 mg/kg/天)。
  • 无患者游离分数在5-10%范围内,中位游离分数为48%,范围为15-89%。
  • 总浓度与游离浓度相关性差(r=0.43),仅2例患者两者分类一致(均在参考范围内)。
  • 白蛋白校正方程预测游离浓度的相关性为r=0.45。
  • 疑似药物不良事件:10例患者发生,其中高氨血症7/12(58%),转氨酶升高2/15(13%),血小板减少5/15(33%)。

关键数值与推荐

  • 参考浓度范围:总丙戊酸50-125 mg/L,游离丙戊酸5-17 mg/L。

临床怎么用

  • ICU患者使用丙戊酸时应直接监测游离浓度,不应依赖总浓度或白蛋白校正公式。

局限性

  • 样本量小(15例),为观察性研究,需进一步研究确定ICU患者丙戊酸剂量调整和监测的最佳实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The free fraction of valproate (the pharmacologically active moiety, normally 5-10%) may vary significantly in critically ill patients, but this topic is understudied, with only four prior intensive care unit (ICU) case reports. The objective of this study was to evaluate the range of valproate plasma protein binding in ICU patients. DESIGN: Observational study of consecutive ICU patients. SETTING: Neurocritical and medical critical care services in a nonuniversity academic medical center. PATIENTS: Consecutive ICU patients treated with valproate with serum albumin less than 4 g/dl. MEASUREMENTS AND MAIN RESULTS: Simultaneous total and free trough serum valproate concentrations were measured as were serum creatinine, blood urea nitrogen, albumin, platelets, and transaminase values. The reference concentration range was 50-125 mg/L (total) and 5-17 mg/L (free). Valproate concentrations were categorized as within reference range, low, or high, and as concordant if both concentrations were in the same category. Data are reported as median (interquartile range). Fifteen patients (nine men) were evaluated. The median age was 63 (34-70) years. The valproate dose was 3 g/day (35 mg/kg/day). No patient had a valproate free fraction of 5-10%; the median was 48%, and the range was 15-89%. Total and free concentrations showed poor correlation (0.43) and were concordant in only two patients (both in the reference range). Free valproate concentration was poorly predicted by an equation correcting for albumin (r = 0.45). Suspected adverse drug events occurred in 10 patients: hyperammonemia in 7 of 12 tested (58%), elevated transaminases in 2 of 15 (13%), and thrombocytopenia in 5 of 15 (33%). CONCLUSIONS: Protein binding of valproate was highly inconsistent in this cohort of ICU patients, and total valproate concentrations did not predict free concentrations, even when correcting for albumin. Additional research to define best practice for dosing and monitoring valproate and the relationship between free valproate concentrations and clinical or adverse effects in ICU patients is needed.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Riker RR, Gagnon DJ, Hatton C, et al. Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review. Pharmacotherapy. 2017. PMID: 28173638. doi:10.1002/phar.1912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。